Dry Eye Syndrome Market Report 2026

The dry eye syndrome market size has grown strongly in recent years. It will grow from $4.17 billion in 2025 to $4.45 billion in 2026 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to increasing prevalence of dry eye syndrome, growing geriatric population, rising screen time and digital device usage, increasing awareness about eye health, advancements in artificial tear formulations.

The dry eye syndrome market size is expected to see strong growth in the next few years. It will grow to $5.96 billion in 2030 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to development of novel drug delivery systems, growth in personalized medicine, rising adoption of wearable eye care devices, expansion of online pharmacy channels, increasing research in natural and herbal eye care products. Major trends in the forecast period include advanced tear film diagnostics, novel drug delivery systems, personalized dry eye treatments, natural and herbal formulations, wearable eye care devices.

The expanding aging population is anticipated to drive the growth of the dry eye syndrome market in the coming years. The aging population represents a demographic shift marked by a rising proportion of elderly individuals within the overall population. This trend significantly contributes to the growth of dry eye syndrome, as advancing age is closely associated with a higher prevalence of the condition. As the number of older adults continues to rise, demand for effective treatments and long-term management solutions for dry eye syndrome is also expected to increase. For example, in October 2025, according to the World Health Organization, a Switzerland-based United Nations organization, by 2030, one in six people worldwide will be aged 60 years or older, with the global population in this age group projected to double to 2.1 billion by 2050. Consequently, the growing aging population is contributing to the expansion of the dry eye syndrome market.

Leading companies operating in the dry eye syndrome market are concentrating on the development of advanced solutions, such as nanomicellar drug delivery technology, to improve treatment efficacy and patient comfort. Nanomicellar drug delivery technology utilizes extremely small micelles to enhance the penetration of active pharmaceutical ingredients into ocular tissues, enabling faster and more effective therapeutic action. This innovation aims to overcome the limitations of conventional therapies and address the significant unmet needs in dry eye disease management. For instance, in April 2023, Sun Pharma, an India-based pharmaceutical company, launched CEQUA, which incorporates NCELL nanomicellar technology. This product became the first dry eye treatment in India to use this technology and delivers improved drug penetration compared with cyclosporine emulsion 0.05%. Supported by several years of clinical experience in the United States and other regions, CEQUA offers faster symptom relief with good patient comfort from the beginning of treatment. The launch addresses the increasing burden of dry eye disease in India, where extended screen exposure has contributed to rising incidence rates.

In July 2024, Bausch + Lomb, a Canada-based eye health company, acquired Trukera Medical for an undisclosed amount. Through this acquisition, Bausch + Lomb seeks to enhance its dry eye disease capabilities and broaden its diagnostic technology portfolio to improve preoperative assessment and clinical outcomes. Trukera Medical is a US-based company that provides ophthalmic diagnostic solutions, including the ScoutPro tear osmolarity system used in the detection and management of dry eye disease.

Major companies operating in the dry eye syndrome market are Allergan plc, Novartis AG, Otsuka Pharmaceutical Co. Ltd., Santendo Pharmaceutical Co. Ltd., Sentiss Pharma Pvt. Ltd., Johnson & Johnson, Alcon Vision LLC, Akorn Operating Company LLC, Sun Pharmaceutical Industries Ltd., Bausch Health Companies Inc., AbbVie Inc., I-MED Pharma Inc., AFT Pharmaceuticals, Horus Pharma, Novaliq GmbH, OASIS Medical, Prestige Consumer Healthcare, VISUfarma, Alimera Science, Kala Pharmaceuticals Inc., Nicox S.A., EyeGate Pharmaceuticals Inc., ReVision Therapeutics Inc., Itear Medical.

North America was the largest region in the dry eye syndrome market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global dry eye syndrome market report during the forecast period. The regions covered in the dry eye syndrome market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the dry eye syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the dry eye syndrome market by increasing the cost of imported active pharmaceutical ingredients, advanced eye care devices, and diagnostic equipment. This has impacted product segments such as liquid drops and gel formulations, particularly in regions like North America and Europe that rely on imports. While tariffs may slow down the adoption of premium products, they also encourage local manufacturing and innovation in cost-effective eye care solutions, benefiting domestic players in the long term.

The dry eye syndrome market research report is one of a series of new reports that provides dry eye syndrome market statistics, including dry eye syndrome industry global market size, regional shares, competitors with a dry eye syndrome market share, detailed dry eye syndrome market segments, market trends and opportunities, and any further data you may need to thrive in the dry eye syndrome industry. This dry eye syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Dry eye syndrome, often referred to as dry eye disease, is a common condition in which the eyes either do not produce sufficient tears or generate tears of poor quality. Dry eye occurs when tear production is inadequate to keep the eyes properly lubricated, leading to discomfort, irritation, and inflammation of the eyes.

The main types of products used for dry eye syndrome include liquid drops, gels, liquid wipes, eye ointments, and others. Liquid eye drops are fluid formulations that are applied directly to the eyes to provide moisture, lubrication, and relief from dryness and irritation. These products include a range of treatments such as corticosteroids, artificial tears, oral omega supplements, lubricating agents, and others. They are distributed through both offline and online channels and are used to treat evaporative and aqueous forms of dry eye disease. These products are utilized across various settings, including hospitals and clinics, medical laboratories, and others.

The dry eye syndrome market includes revenues earned by entities by providing services such as dry eye diagnosis, treatment of dry eye syndrome, prescribed medications, antibiotics, humidifiers, and protective eyewear. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.